Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder

Fung, Simon; Shirley, Matt

doi:10.1007/s40263-023-00995-9

Cited by 4 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, other molecules are gaining interest as potential therapeutic targets in NMO. Monoclonal antibodies directed at complement C5, IL-6R, and B cell CD19 have shown effectiveness in randomized controlled trials ( Traboulsee et al, 2020 ; Romeo, 2021 ; Nie and Blair, 2022 ; Fung and Shirley, 2023 ).…”

Section: B Cells In Chronic and Neurodegenerative Pathologies Of The Cnsmentioning

confidence: 99%

Intruders or protectors – the multifaceted role of B cells in CNS disorders

Aspden,

Murphy,

Kashlan

et al. 2024

Front. Cell. Neurosci.

View full text Add to dashboard Cite

B lymphocytes are immune cells studied predominantly in the context of peripheral humoral immune responses against pathogens. Evidence has been accumulating in recent years on the diversity of immunomodulatory functions that B cells undertake, with particular relevance for pathologies of the central nervous system (CNS). This review summarizes current knowledge on B cell populations, localization, infiltration mechanisms, and function in the CNS and associated tissues. Acute and chronic neurodegenerative pathologies are examined in order to explore the complex, and sometimes conflicting, effects that B cells can have in each context, with implications for disease progression and treatment outcomes. Additional factors such as aging modulate the proportions and function of B cell subpopulations over time and are also discussed in the context of neuroinflammatory response and disease susceptibility. A better understanding of the multifactorial role of B cell populations in the CNS may ultimately lead to innovative therapeutic strategies for a variety of neurological conditions.

show abstract

Section: B Cells In Chronic and Neurodegenerative Pathologies Of The Cnsmentioning

confidence: 99%

Intruders or protectors – the multifaceted role of B cells in CNS disorders

Aspden,

Murphy,

Kashlan

et al. 2024

Front. Cell. Neurosci.

View full text Add to dashboard Cite

show abstract

Monoclonal antibodies in neuro-ophthalmology

Keehn,

Yazdian,

Hunt

et al. 2024

Saudi Journal of Ophthalmology

View full text Add to dashboard Cite

Neuro-ophthalmologic diseases include a broad range of disorders affecting the afferent and efferent visual pathways. Recently, monoclonal antibody (mAb) therapies have emerged as a promising targeted approach in the management of several of these complex conditions. Here, we describe the mechanism-specific applications and advancements in neuro-ophthalmologic mAb therapies. The application of mAbs in neuro-ophthalmologic diseases highlights our increasing understanding of disease-specific mechanisms in autoimmune conditions such as neuromyelitis optica, thyroid eye disease, and myasthenia gravis. Due to the specificity of mAb therapies, applications in neuro-ophthalmologic diseases have yielded exceptional clinical outcomes, including both reduced rate of relapse and progression to disability, visual function preservation, and quality of life improvement. These advancements have not only expanded the range of treatable neuro-ophthalmologic diseases but also reduced adverse events and increased the response rate to treatment. Further research into neuro-ophthalmologic disease mechanisms will provide accurate and specific targeting of important disease mediators through applications of future mAbs. As our understanding of these diseases and the relevant therapeutic targets evolve, we will continue to build on our understanding of how mAbs interfere with disease pathogenesis, and how these changes improve clinical outcomes and quality of life for patients.

show abstract

Efficacy of satralizumab therapy in the treatment of NMOSD

Krzyżanowska,

Kozon,

Olszewski

et al. 2023

Prosp. Pharm. Sc.

View full text Add to dashboard Cite

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is associated with the presence of autoantibodies to anti–aquaporin-4 (AQP4-IgG). Interleukin-6 plays a key role in the pathogenesis of this disorder. Satralizumab, a humanized monoclonal antibody, targets the interleukin-6 receptor thus affects the course of the disease. In Poland, satralizumab treatment has been offered free of charge by the public health service since November 2021. The results of SAkura studies demonstrate the long terms efficacy of satralizumab and provide evidence that satralizumab reduces the risk of relapse in patients with aquaporin-4-immunoglobulin G (IgG)–seropositive (AQP4-IgG+) NMOSD.

show abstract

Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder

Abstract: This plain language summary represents the opinions of the authors. For a full list of declarations, including funding, author disclosure statements, and copyright information, please see the full text online.

Cited by 4 publications

References 25 publications

Intruders or protectors – the multifaceted role of B cells in CNS disorders

Intruders or protectors – the multifaceted role of B cells in CNS disorders

Monoclonal antibodies in neuro-ophthalmology

Efficacy of satralizumab therapy in the treatment of NMOSD

Contact Info

Product

Resources

About